Literature DB >> 17116679

The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.

Vincent H Tam1, Arnold Louie, Mark R Deziel, Weiguo Liu, George L Drusano.   

Abstract

We determined the relationship between garenoxacin exposure and quinolone-resistant subpopulations for three bacterial isolates in an in vitro hollow-fiber infection model. An "inverted-U" relationship was identified wherein resistant subpopulations rose initially and then declined with increasing exposure, until reaching a threshold that prevented resistance amplifications. Different targets for the area under the concentration-time curve over 24 h/MIC ratio were required for different bacteria.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17116679      PMCID： PMC1797751          DOI： 10.1128/AAC.00334-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Molecular mechanisms that confer antibacterial drug resistance.

Authors:  C Walsh
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

2.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

3.  Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; Robert Leary; George L Drusano
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

4.  Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Nelson L Jumbe; Arnold Louie; Michael H Miller; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

Authors:  F J Schmitz; B Hofmann; B Hansen; S Scheuring; M Lückefahr; M Klootwijk; J Verhoef; A Fluit; H P Heinz; K Köhrer; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

7.  Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.

Authors:  J A Bilello; G Bauer; M N Dudley; G A Cole; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226
  8 in total
  58 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 3.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 4.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 5.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Authors:  G L Drusano; William Hope; Alasdair MacGowan; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

7.  Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Authors:  G L Drusano; Robert A Bonomo; Nadzeya Bahniuk; Juergen B Bulitta; Brian Vanscoy; Holland Defiglio; Steven Fikes; David Brown; Sarah M Drawz; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

Review 8.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

9.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.

Authors:  G L Drusano; Weiguo Liu; Christine Fregeau; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.